BresaGen has concluded an agreement with Indian firm BV BioCorp, to register and distribute BresaGen's G-CSF for leukaemia and an undisclosed product in India, Sri Lanka, Bangladesh, and Nepal.

Julie Nutting has stepped down as both CEO and director of Sydney-based Psiron (ASX:PSX), positions she has held since December 2003.

Adelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS).

Brisbane biotech Tissue Therapies (ASX:TIS) has completed a placement to investors, raising AUD$1.6 million before costs.

Sydney biotech Psiron (ASX:PSX) will be the first client for rejuvenated Adelaide biotechnology manufacturer BresaGen's new pilot production plant for therapeutics produced in mammalian cell cultures.

Adelaide-based venture and development capital firm Paragon Equity has invested more than $AUD850,000 to acquire a 10 per equity holding of Adelaide biopharma BresaGen (ASX:BGN).

Adelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.

Selwyn Snell has resigned as the CEO and a director of BioProspect (ASX:BPO), after three years with the company.

BresaGen (ASX:BGN) has been awarded a Commercial Infrastructure Grant of AUD$200,000 from Bio Innovation SA, the South Australian government's biotechnology agency.

The main message to come out of a survey of Australian genomics and proteomics companies, conducted by health care analysts Frost and Sullivan, was that the industry needs more collaboration between academia, companies and those providing funding to engender investor confidence.

The dark clouds over venerable Adelaide biopharma BresaGen (ASX:BGN) have parted, revealing a little blue sky. But the resurrected company's business plan is focused on terra firma -- it is going back to its roots as a service company.